This will play a video. - Older woman baking cookies with her granddaughter

ATRIAL FIBRILLATION MANAGEMENT CARDIAC DIAGNOSTICS & MONITORING

Ongoing cardiac monitoring for the management of atrial fibrillation
Alert Important Safety Information

MONITORING PATIENTS

Patients with asymptomatic episodes are at equal risk for stroke as symptomatic patients.1

  • 69% of patients had at least one AF recurrence2
  • 56% of the recurrent AF being asymptomatic*3
  • 3X increase in asymptomatic episodes post-ablation3

Pie chart showing patients with asymptomatic episodes are at equal risk for stroke as symptomatic patients

HRS AF Ablation Guidelines

  • Prior to undergoing a catheter ablation procedure, it is important to confirm that a patient’s symptoms result from AF and to determine whether a patient has paroxysmal or persistent AF. This is of importance as the ablation technique, procedure outcome, and anticoagulation strategies employed … may be impacted by the accurate characterization of the AF type and burden.4
  • Patients in whom discontinuation of systemic anticoagulation is being considered should consider undergoing continuous ECG monitoring to screen for asymptomatic AF/AFL/AT.5
Reveal LINQ ICM on blue background

Cardiac Monitoring for your AF Patients

Continuous cardiac monitoring leads to more actionable events than conventional monitoring.6

Build a diagnostic picture by continuously monitoring AF burden, heart rate variability, and daily activity with Reveal LINQ™ insertable cardiac monitor (ICM).

Reveal LINQ ICM provides physicians with longitudinal data to objectively determine both asymptomatic and symptomatic AF. This data results in the measure of true AF burden and accurate characterization of the AF type to effectively guide therapy decisions.3,7

data-driven decisions

  1. AT/AF total time per day 
    This trend data is based on a count of 2-minute periods when an AT/AF episode is detected or in progress.
  2. Ventricular rate during AT/AF
    The daily average ventricular rate is derived from the number of ventricular beats during AT/AF episodes and the total time in AT/AF for that day.
  3. Average ventricular rate
    The average day and night heart rates are derived from the sum and number of R-R intervals during the periods defined as “day” and “night.”
  4. Patient activity
    The sum of patient activity in hours per day.

  5. Heart rate variability 
    Median ventricular interval calculated every 5 minutes.

CARDIAC COMPASS™ REPORT  — 90-DAY VIEW

Graph of a Cardiac Compass Report showing AF

Arrhythmia Management

Reveal LINQ ICM allows physicians to continually monitor the ongoing change in AF burden so that treatment can be initiated or changed on a timely basis.8-10

  • Case planning guidance
  • Symptom-rhythm correlation
  • Assessment of drug therapy
  • Objective measurement of AF burden
  • Determination of therapy success
    (e.g., post-AF ablation cardioversion)

CareAlert™ notifications†

Allow for customization by clinic and/or individual patient.

  • AF of any duration
  • AF burden
  • Ventricular rate
  • Symptom + Auto Detect
  • Ventricular rate during AF burden

 

INDUSTRY-LEADING  TruRhythm DETECTION

Our newest detection algorithms streamline
episode review without sacrificing sensitivity.

INTELLIGENT

decorative element

Smart filtering algorithm improves detection accuracy for Brady & Pause. 

ACTIONABLE

decorative element

Streamlined episodes & report updates simplify data review. 

EXCLUSIVE ALGORITHMS

decorative element

Significantly reduce false positives while preserving sensitivity.10,11

Features 

  • 99.7%: Highest published AF detection accuracy on the market streamlines data review13
  • 3 years: Up to 3-year longevity for long-term monitoring14
  • MRI Conditional: Safe for MRI at 1.5 and 3.0T even on the same day of insertion‡14

JOIN OUR EMAIL LIST

Receive updates & ongoing information.

Sign Up Now

EXPERIENCE THE REVEAL LINQ ADVANTAGE

Learn how Reveal LINQ ICM compares for accuracy and longevity.

SEE THE DIFFERENCE
*

Based on clinical evidence.

†

Medtronic CareAlert™ notifications are not intended to be used as the sole basis for making decisions about patient medical care.

‡

Reveal LINQ has been demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal™ ICM clinician manual or MRI technical manual for more details.

1

Bakhai A, Darius H, De Caterina R, et al. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms. Eur Heart J Qual Care Clin Outcomes. October 1, 2016;2(4):299-305.

2

Tondo C, Tritto M, Landolina M, et al. Rhythm-symptom correlation in patients on continuous monitoring after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. February 2014;25(2):154-160.

3

Verma A, Champagne J, Sapp J, et al. Discerning the Incidence of Symptomatic and Asymptomatic Episodes of Atrial Fibrillation Before and After Catheter Ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. January 28, 2013;173(2):149-156.

4

Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm. April 2012;9(4):632-696.

5

Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. January 1, 2018;20(1):e1-e160.

6

Kapa S, Epstein AE, Callans DJ, et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. J Cardiovasc Electrophysiol. August 2013;24(8):875-881.

7

Wechselberger S, Kronborg M, Huo Y, et al. Continuous monitoring after atrial fibrillation: the LINQ AF study. Europace. November 1, 2018;20(FI_3):f312-f320.

8

Sinha S. The Impact of Atrial Fibrillation: Paroxysmal Atrial Fibrillation: Diagnosis, Progression, and Stroke Risk. MedPageToday. Available at: https://archive.li/DU7LI. Accessed February 25, 2019.

9

Mascarenhas DA, Farooq MU, Ziegler PD, Kantharia BK. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. Europace. June 2016;18(6):799-806.

10

Passman R, Bernstein RA. New Appraisal of Atrial Fibrillation Burden and Stroke Prevention. Stroke. February 2016;47(2):570-576.

11

Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. November 1, 2018;20(Fl_3):f321-f328.

12

Passman RS, Rogers JD, Sarkar S, et al. Development and validation of a dual sensing scheme to improve accuracy of bradycardia and pause detection in an insertable cardiac monitor. Heart Rhythm. July 2017;14(7):1016-1023.

13

TruRhythm Detection Algorithms. Medtronic data on file. 2017.

14

Reference the Reveal LINQ ICM Clinician Manual for usage parameters.